Ibrance
Product Images NDC 63539-188

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ibrance (NDC 63539-188). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by U.s. Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Ibrance 01)

Chemical structure of Ibrance showing its molecular framework with multiple ring systems including a piperazine ring and heterocyclic moieties.*

FDA Label Image

Figure 1 (Ibrance 02)

A Kaplan-Meier survival curve showing progression-free survival probability over time in months. The graph compares two groups: palbociclib plus letrozole (solid line) and placebo plus letrozole (dashed line). The x-axis represents time in months, and the y-axis shows progression-free survival probability as a percentage. Below the plot is a table listing the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 2 (Ibrance 03)

A Kaplan-Meier survival curve chart comparing progression-free survival probability (%) over time (months) for patients treated with palbociclib plus fulvestrant versus placebo plus fulvestrant. The chart includes the number of patients at risk for each group at several time points along the x-axis.*

FDA Label Image

Logo (Ibrance 04)

A survival probability Kaplan-Meier curve graph comparing overall survival probability percentages over time in months between two treatment groups: palbociclib plus fulvestrant (solid line) and placebo plus fulvestrant (dashed line). The graph includes corresponding patient numbers at risk across different time points.*

FDA Label Image

Principal Display Panel (125 mg Capsule Bottle Label)

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

FDA Label Image

Principal Display Panel (75 mg Capsule Bottle Label)

Ibrance 125 mg capsules label by U.S. Pharmaceuticals and Pfizer. The label states it is a professional sample not for sale, contains 21 capsules, and is intended for oncology use only. Storage instructions and dosage information for palbociclib are also provided.*

FDA Label Image

Ibrance 08

Ibrance 100 mg capsules label showing the active ingredient palbociclib. The label includes storage instructions between 20°C to 25°C, dosage information confirming each capsule contains 100 mg of palbociclib, and indicates it contains 21 capsules. It is distributed by U.S. Pharmaceuticals and Pfizer, with a note that it is a professional sample not for sale.*

FDA Label Image

Ibrance 09

Label for Ibrance (palbociclib) capsules, 75 mg strength, containing 21 capsules. The label indicates it is a professional sample not for sale, distributed by U.S. Pharmaceuticals in collaboration with Pfizer Inc. Storage instructions specify 20°C to 25°C with permitted excursions. Dosage information notes each capsule contains 75 mg of palbociclib.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.